Skip to content

CAEX: what changed

BE 0451.783.141NACE 46.460, Wholesale of pharmaceutical and medical goodsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
-€35,823
2024 · -€31,183-€4,640
Equity
-€882,245
2024 · -€846,423-€35,823
Cash
€296
2024 · €1,294-€999
Balance sheet total
€270,481
2024 · €1,421+€269,060

Largest movements

2024 to 2025
Assets
  • Receivables within one year +€270,059

    up €270,059 (+212,913%), from €127 to €270,186

    of which Trade receivables: +€270,000

Equity and liabilities
  • Debts after one year +€304,845

    up €304,845 (+36.0%), from €846,958 to €1.2m

  • Profit (loss) carried forward -€35,823

    down €35,823 (-3.9%), from -€914,623 to -€950,445

Income statement
  • Financial charges +€4,600

    up €4,600 (+16.5%), from €27,902 to €32,503

  • Gross operating margin -€31

    down €31 (-1.2%), from -€2,646 to -€2,676

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 -€31,183
Gross operating margin -€31
Other operating charges -€9
Financial charges -€4,600
Result 2025 -€35,823
lowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations -€305,844
Investment €0
Financing +€304,845
Cash 2024 €1,294
Net result for the year -€35,823
Receivables within one year -€270,059
Trade debts +€38
Debts after one year +€304,845
Cash 2025 €296
brings cash intakes cash out
Every line side by side 30 lines
Line Code 2024 2025 Change %
Total assets 20/58 €1,421 €270,481 +€269,060 +18,933%
Current assets 29/58 €1,421 €270,481 +€269,060 +18,933%
Amounts receivable within one year 40/41 €127 €270,186 +€270,059 +212,913%
Trade receivables 40 - €270,000 +€270,000
Other amounts receivable 41 €127 €186 +€59 +46.3%
Cash at bank and in hand 54/58 €1,294 €296 -€999 -77.2%
Total equity and liabilities 10/49 €1,421 €270,481 +€269,060 +18,933%
Equity 10/15 -€846,423 -€882,245 -€35,823 -4.2%
Contributions 10/11 €62,000 €62,000 = 0.0%
Capital 10 €62,000 €62,000 = 0.0%
Issued capital 100 €62,000 €62,000 = 0.0%
Reserves 13 €6,200 €6,200 = 0.0%
Non-distributable reserves 130/1 €6,200 €6,200 = 0.0%
Legal reserve 130 €6,200 €6,200 = 0.0%
Profit (loss) carried forward 14 -€914,623 -€950,445 -€35,823 -3.9%
Amounts payable 17/49 €847,844 €1,152,727 +€304,883 +36.0%
Amounts payable after more than one year 17 €846,958 €1,151,803 +€304,845 +36.0%
Other amounts payable 178/9 €846,958 €1,151,803 +€304,845 +36.0%
Amounts payable within one year 42/48 €731 €768 +€38 +5.1%
Trade debts 44 €731 €768 +€38 +5.1%
Suppliers 440/4 €731 €768 +€38 +5.1%
Accrued charges and deferred income 492/3 €155 €155 = 0.0%
Other operating charges 640/8 €635 €643 +€9 +1.3%
Gross operating margin 9900 -€2,646 -€2,676 -€31 -1.2%
Operating profit (loss) 9901 -€3,281 -€3,320 -€39 -1.2%
Financial charges 65/66B €27,902 €32,503 +€4,600 +16.5%
Recurring financial charges 65 €27,902 €32,503 +€4,600 +16.5%
Profit (loss) for the period before taxes 9903 -€31,183 -€35,823 -€4,640 -14.9%
Profit (loss) for the period 9904 -€31,183 -€35,823 -€4,640 -14.9%
Profit (loss) for the period to be appropriated 9905 -€31,183 -€35,823 -€4,640 -14.9%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice

Capitalisation rate 12% result over 3 years earnings weight 50%

The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.

Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.

Adjusted equity -€882,245

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
-€882,245
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
-€882,245

Capitalised earnings

net result for the year (9904)
2025
-€35,823
2024
-€31,183
2023
-€41,117
2022
-€72,201
excluding non-recurring income and charges
-€15,165
2021
-€98,526
Average result
-€36,041
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
not meaningful, as the average result is zero or negative

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.